PubMed Health⌕ Search

PubMed · 11175433

Animal models with construct validity for schizophrenia.

Abstract

Developing animal models for psychiatric disorders is a complicated process. This is principally due to our relatively limited knowledge of the processes underlying such complicated illnesses as depression and schizophrenia. Unfortunately this can lead to a vicious circle. Our limited knowledge of the disease leads to the inability to develop proper animal models, which will lead to an inability to increase our knowledge about neuronal mechanisms underlying the illness. In the present review we have tried to show that with respect to schizophrenia the situation is slowly changing. Using electrophysiological and psychological methods, clinicians begin to understand the psychopathological processes underlying the schizophrenic process. Preclinical researchers have tried to use this knowledge to develop animal models in which hypotheses can be tested and possible insight into mechanisms underlying the disease can be gained. In the present review three different animal models are presented. These are based on the construct that schizophrenic patients are disturbed in their information processing. More precisely the first two animal models are based on the construct that schizophrenic patients are less able to differentiate between relevant and irrelevant stimuli. The analysis of the literature suggests that the amphetamine-induced distruption of latent inhibition (and probably blocking), and the phencyclidine-induced disturbances in the startle response might provide two interesting animal models with construct, face and predictive validity for schizophrenia. This third model deals with the amphetamine-induced changes in the behaviour of socially living monkeys. This model seems to be related to both positive and negative symptoms of schizophrenia and is based on the construct that the negative symptoms are due to a compensatory mechanism which protects the subjects from "sensory flooding". The amphetamine-induced changes in behaviour of socially living monkeys seem to represent an example of an animal model in which both positive symptoms (stereotypy) and negative symptoms (social isolation) occurs. The construct validity of this model is still unclear, but pharmacological studies suggest that, apart from the face validity, the model also has a certain predictive validity. The models discussed in the present review can help us to increase our insight in neuronal structures underlying information processing disturbances. Structures known to be implicated in these models include the hippocampus, amygdala and ventral striatum.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B.A. Ellenbroek, A.R. Cools. 1990. Animal models with construct validity for schizophrenia.. https://pubmed.ncbi.nlm.nih.gov/11175433/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗